Table 2.
Characteristics of the patients included in the secondary analysis.
| Non-platinum-based 1LTa (N = 28) | Platinum-based 3- and 4-agents 1LTb (N = 40) | Platinum-based 2 agents 1LTc (N = 9) | |
|---|---|---|---|
| Age at diagnosis (years), median (range) | 61 (38–75) | 57 (35–72) | 66 (51–72) |
| Gender, N (%) | |||
| Female | 19 (68) | 17 (42) | 4 (44) |
| Male | 9 (32) | 23 (58) | 5 (56) |
| ECOG PS at diagnosis, N (%) | |||
| 0 | 20 (71) | 23 (60) | 3 (33) |
| 1 | 7 (25) | 15 (40) | 4 (44) |
| 2 | 1 (4) | 0 | 2 (23) |
| NA | 0 | 2 | 0 |
| Liver metastases at diagnosis, N (%) | |||
| Yes | 22 (79) | 31 (77) | 7 (78) |
| No | 6 (21) | 9 (23) | 2 (22) |
| gBRCA PV status, N (%) | |||
| gBRCA1 | 7 (25) | 9 (23) | 3 (33) |
| gBRCA2 | 21 (75) | 31 (77) | 5 (56) |
| gBRCA 1 + 2 | 0 | 0 | 1 (11) |
1LT first-line therapy, PS performance status, NA not available, gBRCA germline BRCA, PV pathogenic variant.
a25 patients were treated with Nab-paclitaxel plus gemcitabine (AG) [4], 2 with AG-based therapy within a clinical trial [25, 26], 1 with Nab-Paclitaxel plus Fluorouracil and Irinotecan (Nab-FOLFIRI) within a clinical trial [27].
b22 patients received FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) [5], modified FOLFIRINOX (mFOLFIRINOX) [21] or FOLinic acid, Fluorouracil, Oxaliplatin and IRInotecan (FOLFOXIRI) [22], 14 PAXG [6], 2 Cisplatin, Epirubicin, Capecitabine and Gemcitabine (PEXG) [23], 2 Cisplatin plus AG.
c5 patients were treated with Gemcitabine plus Oxaliplatin (GEMOX) [24], 4 with FOLFOX [9].